Last reviewed · How we verify
Experimental: Aspirin monotherapy
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation. Used for Secondary prevention of cardiovascular events (myocardial infarction, stroke), Primary prevention of cardiovascular disease in high-risk patients.
At a glance
| Generic name | Experimental: Aspirin monotherapy |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) / Antiplatelet agent |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2, preventing the synthesis of thromboxane A2 and prostaglandins. This dual action reduces platelet clumping and inflammatory mediator production, making it effective for cardiovascular protection and pain relief. As monotherapy in this context, it is used as a standalone antiplatelet agent rather than in combination regimens.
Approved indications
- Secondary prevention of cardiovascular events (myocardial infarction, stroke)
- Primary prevention of cardiovascular disease in high-risk patients
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Bruising/bleeding
- Allergic reaction
Key clinical trials
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis (NA)
- Genotype Guided Antiplatelet Therapy in Ischemic Stroke (NA)
- 1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon (NA)
- PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction (PHASE4)
- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation (PHASE3)
- GLOBAL LEADERS Adjudication Sub-Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |